Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL

References

• Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881–2892. doi:10.1182/blood.2020008824
   PubMed Web of Science ®Google Scholar
• Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134–1143. doi:10.1182/blood.2020006965
   PubMed Web of Science ®Google Scholar
• Hilal T, Gea-Banacloche JC, Leis JF. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: linking mechanisms with infections. Blood Rev. 2018;32(5):387–399. doi:10.1016/j.blre.2018.03.004
   PubMed Web of Science ®Google Scholar
• Mauro FR, Giannarelli D, Galluzzo CM, et al. Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). Leukemia. 2021;35(3):737–746. doi:10.1038/s41375-020-0884-z
   PubMed Web of Science ®Google Scholar
• Pleyer C, Ali MA, Cohen JI, et al. Effect of bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. Blood. 2021;137(2):185–189. doi:10.1182/blood.2020008758
   PubMed Web of Science ®Google Scholar
• Pleyer C, Laing KJ, Ali MA, et al. BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL. Blood Adv. 2022;6(6):1732–1740. doi:10.1182/bloodadvances.2021006574
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165–3173. doi:10.1182/blood.2021011568
   PubMed Web of Science ®Google Scholar
• Chang A, Akhtar A, Linderman SL, et al. Humoral responses against SARS-CoV-2 and variants of concern after mRNA vaccines in patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia. J Clin Oncol. 2022;40(26):3020–3031. doi:10.1200/JCO.22.00088
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Rahav G, Levi S, et al. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Blood. 2022;139(5):678–685. doi:10.1182/blood.2021014085
   PubMed Web of Science ®Google Scholar
• Ehmsen S, Asmussen A, Jeppesen SS, et al. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer. Cancer Cell. 2021;39(8):1034–1036. doi:10.1016/j.ccell.2021.07.016
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211. doi:10.1038/s41591-021-01377-8
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Rhead R, Silverwood RJ, et al. Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection. Vaccines. 2022; 10(1):64. doi:10.3390/vaccines10010064
   Google Scholar
• Parry H, McIlroy G, Bruton R, et al. Antibody responses after first and second covid-19 vaccination in patients with chronic lymphocytic leukaemia. Blood Cancer J. 2021;11(7):136. doi:10.1038/s41408-021-00528-x
   PubMed Web of Science ®Google Scholar
• Bagacean C, Letestu R, Al-Nawakil C, et al. Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia. Blood Adv. 2022;6(1):207–211. doi:10.1182/bloodadvances.2021006215
   PubMed Web of Science ®Google Scholar
• Sun CCL, Nierman PK, Kendall EK, et al. Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib. Blood. 2020;136(1):93–105. ():doi:10.1182/blood.2019003715
   PubMed Web of Science ®Google Scholar
• Grupel D, Gazit S, Schreiber L, et al. Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination. Vaccine. 2021;39(38):5337–5340. doi:10.1016/j.vaccine.2021.08.025
   PubMed Web of Science ®Google Scholar
• Ahn IE, Basumallik N, Tian X, et al. Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL. Blood. 2019;133(22):2452–2455. doi:10.1182/blood.2019896688
   PubMed Web of Science ®Google Scholar
• Resman Rus K, Korva M, Knap N, et al. Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay. J Clin Virol. 2021;139:104820. doi:10.1016/j.jcv.2021.104820
   PubMed Web of Science ®Google Scholar
• Bellusci L, Grubbs G, Zahra FT, et al. Antibody affinity and cross-variant neutralization of SARS-CoV-2 omicron BA.1, BA.2 and BA.3 following third mRNA vaccination. Nat Commun. 2022;13(1):4617. doi:10.1038/s41467-022-32298-w
   PubMed Web of Science ®Google Scholar
• CDC. COVID-19 vaccination clinical & professional resources: cdc.gov. 2022. https://www.cdc.gov/vaccines/covid-19/index.html
   Google Scholar
• Benjamini O, Rokach L, Itchaki G, et al. Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Haematologica. 2022;107(3):625–634. doi:10.3324/haematol.2021.279196
   PubMed Web of Science ®Google Scholar
• Dalai SC, Dines JN, Snyder TM, et al. Clinical validation of a novel T-cell receptor sequencing assay for identification of recent or prior SARS-CoV-2 infection. Clin Infect Dis. 2022;75:2079–2087.
   PubMed Web of Science ®Google Scholar
• Greenberger LM, Saltzman LA, Gruenbaum LM, et al. Anti-spike T-cell and antibody responses to SARS-CoV-2 mRNA vaccines in patients with hematologic malignancies. Blood Cancer Discov. 2022;3(6):481–489.
   PubMedGoogle Scholar